Nexvet Biopharma plc
(NASDAQ GM: NVET)
Attention investors who purchased shares of Nexvet Biopharma plc before April 13, 2017:
Rigrodsky & Long is investigating potential claims against the board of directors of Nexvet Biopharma plc concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Zoetis Inc. for $6.72 per share, or approximately $85 million.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Nexvet Biopharma plc (“Nexvet” or the “Company”) (NASDAQ GM: NVET) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Zoetis Inc. (“Zoetis”) (NYSE: ZTS) in a transaction valued at approximately $85 million. Under the terms of the agreement, shareholders of Nexvet will receive $6.72 in cash for each share of Zoetis common stock.
If you own common stock of Zoetis and purchased any shares before April 13, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242, or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.